References
- Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541. https://doi.org/10.1056/NEJMoa055229
- Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: case report. Platelets 2015;26:809-811. https://doi.org/10.3109/09537104.2015.1049138
- Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-263. https://doi.org/10.1182/blood-2008-09-180604
- Gratacap MP, Martin V, Valera MC, et al. The new tyrosine- kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114:1884-1892. https://doi.org/10.1182/blood-2009-02-205328
- Kmira Z, Nesrine BS, Houneida Z, et al. Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 2013;4:59-62. https://doi.org/10.4291/wjgp.v4.i3.59
Cited by
- Dasatinib : Haemorrhagic colitis: case report vol.1697, pp.1, 2018, https://doi.org/10.1007/s40278-018-44696-9